Acute Kidney Injury (AKI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Acute Kidney Injury (AKI) Market Outlook

Thelansis’s “Acute Kidney Injury (AKI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Kidney Injury (AKI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Kidney Injury (AKI) Overview

Acute Kidney Injury (AKI) is a sudden decline in kidney function, determined by elevated serum creatinine levels (indicating impaired kidney excretion) and reduced urine output (oliguria) within a 7-day timeframe. When AKI persists for over 3 months, it is termed Chronic Kidney Disease (CKD). It’s noteworthy that AKI and CKD frequently coexist in patients with preexisting CKD. Acute Renal Failure (ARF) is a clinical syndrome characterized by the abrupt onset of kidney dysfunction, resulting in the accumulation of metabolic toxins and disturbances in fluid, electrolyte, and acid-base balance. The causes of AKI can be categorized into three groups: prerenal (due to reduced renal blood flow, often due to dehydration), intrinsic renal (stemming from kidney-related issues), and postrenal (resulting from inadequate urine drainage beyond the kidneys). In individuals with underlying chronic kidney disease, any factors, particularly dehydration, can lead to AKI alongside chronic renal impairment. Prerenal causes account for around 70% of community-acquired AKI cases. Various medications, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs, can trigger prerenal AKI by affecting renal perfusion or glomerular filtration rate. These drugs can hinder the body’s usual responses to dehydration and may result in reduced renal function. In prerenal AKI, kidney function typically returns to normal once adequate fluid levels are restored, the underlying cause is treated, or the causative medication is discontinued. AKI classification comprises prerenal AKI, acute postrenal obstructive nephropathy, and intrinsic acute kidney diseases. Only “intrinsic” AKI represents a true kidney disease, while prerenal and postrenal AKI are outcomes of non-kidney conditions that reduce glomerular filtration rate (GFR). If prerenal and postrenal conditions persist, they can eventually lead to cellular damage in the kidneys and, consequently, intrinsic renal disease. Risk factors for AKI encompass environmental, socioeconomic, cultural, care-related, acute exposures, and patient-related factors. Clinical presentation varies based on the cause and severity of renal injury, as well as any associated conditions. Most mild to moderate AKI patients exhibit no symptoms and are identified through laboratory tests. In severe cases, patients may experience listlessness, confusion, fatigue, loss of appetite, nausea, vomiting, weight gain, or edema. Severe AKI can also manifest as oliguria (urine output less than 400 mL per day), anuria (urine output less than 100 mL per day), or normal urine volumes (nonoliguric AKI). Additional presentations may include uremic encephalopathy (characterized by a decline in mental status, asterixis, or other neurological symptoms), anemia, or bleeding due to platelet dysfunction caused by uremia. Currently, AKI diagnosis relies on an acute reduction in GFR, indicated by an abrupt increase in serum creatinine levels and a decrease in urine output within a specific timeframe. The primary treatment option is dialysis and supportive care, as no drugs are approved for AKI treatment. Typically, these patients are managed in intensive care units, often with the assistance of nephrologists.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Acute Kidney Injury (AKI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034